Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment
详细信息 查看全文
- 作者：Michael S. Gordona ; mgordon@friendsresearch.org ; Frank J. Voccia ; Terrence T. Fitzgeraldb ; Kevin E. O'Gradyc ; Charles P. O'Briend
- 关键词：Prisoners ; Long-acting naltrexone ; Medical mobile treatment ; Criminal justice
- 刊名：Contemporary Clinical Trials
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：53
- 期：Complete
- 页码：130-136
- 全文大小：437 K
- 卷排序：53
文摘
Extended-release naltrexone (XR-NTX), is an effective treatment for opioid use disorder but is rarely initiated in US prisons or with criminal justice populations. Mobile treatment for chronic diseases has been implemented in a variety of settings. Mobile treatment may provide an opportunity to expand outreach to parolees to surmount barriers to traditional clinic treatment.MethodsMale and female prisoners (240) with pre-incarceration histories of opioid use disorder who are within one month of release from prison will be enrolled in this randomized clinical trial. Participants are randomized to one of two study arms: 1) [XR-NTX-OTx] One injection of long-acting naltrexone in prison, followed by 6 monthly injections post-release at a community opioid treatment program; or 2) [XR-NTX + MMTx] One injection of long-acting naltrexone in prison followed by 6 monthly injections post-release at the patient's place of residence utilizing mobile medical treatment. The primary outcomes are: treatment adherence; opioid use; criminal activity; re-arrest; reincarceration; and HIV risk-behaviors.ResultsWe describe the background and rationale for the study, its aims, hypotheses, and study design.ConclusionsThe use of long-acting injectable naltrexone may be a promising form of treatment for pre-release prisoners. Finally, as many individuals in the criminal justice system drop out of treatment, this study will assess whether treatment at their place of residence will improve adherence and positively affect treatment outcomes.ClinicalTrials.gov: NCT02867124